Quintiles and Almirall form new UK partnership

Quintiles has agreed a long-term deal to promote the respiratory portfolio of the pharmaceutical company Almirall in the UK.

The strategic agreement will commence with the launch of a new inhaler-based long-acting antimuscarinic treatment for chronic obstructive pulmonary disease, which was approved by the European Commission earlier this month.

Almirall and Quintiles have been working together for some time prior to this agreement, with Quintiles conducting part of the clinical study programme for the new drug, as well as providing commercialisation services in multiple European countries.

It is hoped that the new arrangement will make the innovative therapeutic option as accessible as possible to British patients.

Robert Taylor, managing director for UK commercial solutions at Quintiles, said: "This partnership allows our talented and engaged workforce to drive success across the lifecycle of Almirall's respiratory products."

Earlier this month, Quintiles launched Allume, a new go-to-market service that aims to help pharmaceutical companies launch products more efficiently.